InspireMD (NSPR)

The company’s principal product is the CGuard Embolic Prevention System, a carotid stent that combines a self-expanding nitinol frame with MicroNet technology. It is intended for use in carotid artery procedures, where preventing plaque fragments from travelling to the brain is a central clinical concern. Carotid artery disease is associated with elevated stroke risk, and treatment options include surgery, stenting, and medical management depending on patient profile and physician assessment.

InspireMD also has developed the MGuard Prime Embolic Protection System for coronary applications, although its commercial focus is primarily associated with CGuard and the carotid market. The company develops, manufactures, and markets products within a single operating segment centred on carotid and other vascular disease. Its revenue is mainly derived from CGuard sales in markets where the product is available.

For investors, NSPR represents a small medical technology company targeting a specialised segment of interventional vascular care. Its prospects depend on physician adoption, clinical evidence, regulatory clearances, reimbursement conditions, manufacturing execution, and the ability to compete against established vascular device companies. The distinctive element of InspireMD’s approach is the integration of embolic protection directly into the stent design, aiming to address a key procedural risk in carotid artery intervention.